{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:18:52Z","timestamp":1787789932021,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MD Anderson Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["MD Anderson Cancer Center Leukemia SPORE CA100632"],"award-info":[{"award-number":["MD Anderson Cancer Center Leukemia SPORE CA100632"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myelodysplastic syndrome and myeloproliferative neoplasm (MDS\/MPN) overlap syndromes are characterized by the presence of features of both MDS and MPN and have a poor prognosis. We conducted a phase 2 clinical trial evaluating the combination of Azacitidine (AZA) and Ruxolitinib (RUX) in MDS\/MPN, with interim analysis showing an objective response rate of 57%. Herein, we report the final analysis from this clinical trial, including long-term survival data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was an open-label phase 2 clinical trial including adult patients in 2 diagnostic arms: myelofibrosis (arm 1) and MDS\/MPN (arm 2). This manuscript reports outcomes of MDS\/MPN patients. RUX 5\u201320\u00a0mg twice daily (per RUX label) was administered in 28-day cycles, and AZA 25 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1\u20135 was added starting cycle 4. Primary endpoint was objective response rate per the 2015 International Consortium Proposal (ICP) MDS\/MPN response criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 5\/2013 to 8\/2022, 52 patients were treated with a median age of 68 years (range, 39\u201382). Disease subtypes were MDS\/MPN-Unclassifiable in 24 patients (46%), chronic myelomonocytic leukemia in 23 patients (44%), and atypical chronic myeloid leukemia in 5 patients (10%). Majority of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940, 77%) had intermediate-2\/high-risk disease by Dynamic International Prognosis Scoring System criteria. Objective responses were attained in 30 patients (58%), with a median duration of response of 13.6 months (95% CI: 6.4\u201341.1). After a median follow up of 88.5 months, 13 (25%) patients are alive, with median overall survival (OS) of 26.7 months (95% CI: 16.5\u201352.7), 5-year OS 33%. Median OS in MDS\/MPN-U and CMML was 52.7 months (5-year OS 46%) and 17.5 months (5-year OS 27%), respectively. Twelve patients (23%) underwent allogeneic stem cell transplantation; with median OS not reached, 5-year OS 51%. Transformation to acute myeloid leukemia occurred in 13 patients (25%). The most common grade 3\u20135 adverse events (AEs) regardless of attribution were anemia (31, 60%), thrombocytopenia (27, 52%) and pneumonia (17, 33%). AE-related treatment discontinuation occurred in only 3 patients (6%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AZA-RUX therapy led to durable responses and encouraging OS in MDS\/MPN with a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT01787487, (clinicaltrials.gov, date: 2\/6\/2013)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-026-01813-7","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:06:49Z","timestamp":1781604409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome\/myeloproliferative neoplasms"],"prefix":"10.1186","volume":"19","author":[{"given":"Sankalp","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraneel","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Nogueras-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingsha","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyana","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1813_CR1","doi-asserted-by":"publisher","unstructured":"Hyjek E, Vardiman JW. Myelodysplastic\/myeloproliferative neoplasms. Seminars in Diagnostic Pathology. 2011\/11\/01\/ 2011;28(4):283\u2013297. https:\/\/doi.org\/10.1053\/j.semdp.2011.07.002","DOI":"10.1053\/j.semdp.2011.07.002"},{"issue":"7","key":"1813_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1. \/07\/01 2022.","journal-title":"Leukemia"},{"key":"1813_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","volume":"42","author":"E Roman","year":"2016","unstructured":"Roman E, Smith A, Appleton S, et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004-15. Cancer Epidemiol Jun. 2016;42:186\u201398. https:\/\/doi.org\/10.1016\/j.canep.2016.03.011.","journal-title":"Cancer Epidemiol Jun"},{"issue":"1","key":"1813_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/hematology.2020000163","volume":"4","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Lasho T. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology Am Soc Hematol Educ Program Dec. 2020;4(1):460\u20134. https:\/\/doi.org\/10.1182\/hematology.2020000163.","journal-title":"Hematology Am Soc Hematol Educ Program Dec"},{"issue":"1","key":"1813_CR5","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1038\/bcj.2015.113","volume":"15","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J Jan. 2016;15(1):e385. https:\/\/doi.org\/10.1038\/bcj.2015.113.","journal-title":"Blood Cancer J Jan"},{"issue":"19","key":"1813_CR6","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","volume":"132","author":"P Bose","year":"2018","unstructured":"Bose P, Nazha A, Komrokji RS, et al. Mutational landscape of myelodysplastic\/myeloproliferative neoplasm\u2013unclassifiable. Blood. 2018;132(19):2100\u20133. https:\/\/doi.org\/10.1182\/blood-2018-05-848473.","journal-title":"Blood"},{"issue":"4","key":"1813_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.26828","volume":"98","author":"MM Patnaik","year":"2023","unstructured":"Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023;98(4):681\u20139. https:\/\/doi.org\/10.1002\/ajh.26828.","journal-title":"Am J Hematol"},{"issue":"17","key":"1813_CR8","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","volume":"24","author":"SA Wang","year":"2014","unstructured":"Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms. Blood Apr. 2014;24(17):2645\u201351. https:\/\/doi.org\/10.1182\/blood-2014-02-553800.","journal-title":"Blood Apr"},{"key":"1813_CR9","doi-asserted-by":"publisher","unstructured":"Chaudhury A, Komrokji RS, Al Ali NH, Zhang L, Vafaii P, Lancet JE. Prognosis and Outcomes in MDS-MPN Unclassifiable: Single Institution Experience of a Rare Disorder. Blood. 2015\/12\/03\/ 2015;126(23):1698. https:\/\/doi.org\/10.1182\/blood.V126.23.1698.1698","DOI":"10.1182\/blood.V126.23.1698.1698"},{"key":"1813_CR10","doi-asserted-by":"publisher","unstructured":"Mangaonkar AA, Swoboda DM, Coltro G et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020\/02\/01 2020;34(2):656\u201361. https:\/\/doi.org\/10.1038\/s41375-019-0574-x","DOI":"10.1038\/s41375-019-0574-x"},{"issue":"17\u201318","key":"1813_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","volume":"131","author":"K Geissler","year":"2019","unstructured":"Geissler K, J\u00e4ger E, Barna A, et al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr Sep. 2019;131(17\u201318):410\u20138. https:\/\/doi.org\/10.1007\/s00508-019-1526-1.","journal-title":"Wien Klin Wochenschr Sep"},{"key":"1813_CR12","doi-asserted-by":"publisher","unstructured":"Casta\u00f1o-D\u00edez S, L\u00f3pez-Guerra M, Bosch-Casta\u00f1eda C, et al. Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes. Cancers (Basel) Aug. 2022;25(17). https:\/\/doi.org\/10.3390\/cancers14174107.","DOI":"10.3390\/cancers14174107"},{"key":"1813_CR13","doi-asserted-by":"publisher","unstructured":"Carr RM, Vorobyev D, Lasho T et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications. 2021\/05\/18 2021;12(1):2901. https:\/\/doi.org\/10.1038\/s41467-021-23186-w","DOI":"10.1038\/s41467-021-23186-w"},{"issue":"7","key":"1813_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3324\/haematol.2021.279500","volume":"1","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM. How I diagnose and treat chronic myelomonocytic leukemia. Haematologica Jul. 2022;1(7):1503\u201317. https:\/\/doi.org\/10.3324\/haematol.2021.279500.","journal-title":"Haematologica Jul"},{"key":"1813_CR15","doi-asserted-by":"publisher","first-page":"801524","DOI":"10.3389\/fonc.2021.801524","volume":"11","author":"K Liapis","year":"2021","unstructured":"Liapis K, Kotsianidis I. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment? Front Oncol. 2021;11:801524. https:\/\/doi.org\/10.3389\/fonc.2021.801524.","journal-title":"Front Oncol"},{"key":"1813_CR16","doi-asserted-by":"publisher","first-page":"884723","DOI":"10.3389\/fonc.2022.884723","volume":"12","author":"A Symeonidis","year":"2022","unstructured":"Symeonidis A, Chondropoulos S, Verigou E, Lazaris V, Kourakli A, Tsirigotis P. Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic\/Myeloproliferative Disorders. Front Oncol. 2022;12:884723. https:\/\/doi.org\/10.3389\/fonc.2022.884723.","journal-title":"Front Oncol"},{"issue":"10","key":"1813_CR17","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/jco.22.00437","volume":"41","author":"R Itzykson","year":"2023","unstructured":"Itzykson R, Santini V, Thepot S, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2023;41(10):1888\u201397. https:\/\/doi.org\/10.1200\/jco.22.00437.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1813_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/leu.2017.186","volume":"32","author":"V Santini","year":"2018","unstructured":"Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia Feb. 2018;32(2):413\u20138. https:\/\/doi.org\/10.1038\/leu.2017.186.","journal-title":"Leukemia Feb"},{"issue":"7","key":"1813_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ajh.25488","volume":"94","author":"T Coston","year":"2019","unstructured":"Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94(7):767\u201379. https:\/\/doi.org\/10.1002\/ajh.25488.","journal-title":"Am J Hematol"},{"issue":"7","key":"1813_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ajh.24735","volume":"92","author":"A Alfonso","year":"2017","unstructured":"Alfonso A, Montalban-Bravo G, Takahashi K, et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol Jul. 2017;92(7):599\u2013606. https:\/\/doi.org\/10.1002\/ajh.24735.","journal-title":"Am J Hematol Jul"},{"issue":"Supplement 1","key":"1813_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2025-488","volume":"146","author":"D Wiseman","year":"2025","unstructured":"Wiseman D, Laight J, Boucher R, et al. ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide\/best supportive care in CMML and other MDS\/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial. Blood. 2025;146(Supplement 1):488\u2013488. https:\/\/doi.org\/10.1182\/blood-2025-488.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1813_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood-2023-181795","volume":"142","author":"D Tremblay","year":"2023","unstructured":"Tremblay D, Csizmar CM, DiNardo CD, et al. Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis. Blood. 2023;142(Supplement 1):321\u2013321. https:\/\/doi.org\/10.1182\/blood-2023-181795.","journal-title":"Blood"},{"issue":"5","key":"1813_CR23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41375-021-01240-2","volume":"35","author":"G Montalban-Bravo","year":"2021","unstructured":"Montalban-Bravo G, Hammond D, DiNardo CD, et al. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021;35(5):1494\u20139. https:\/\/doi.org\/10.1038\/s41375-021-01240-2. \/05\/01 2021.","journal-title":"Leukemia"},{"issue":"4","key":"1813_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cncr.34564","volume":"129","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Darbaniyan F, Kadia TM, et al. A retrospective study of cladribine and low-dose cytarabine\u2013based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023;129(4):560\u20138. https:\/\/doi.org\/10.1002\/cncr.34564.","journal-title":"Cancer"},{"issue":"4","key":"1813_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/leu.2014.8","volume":"28","author":"CD DiNardo","year":"2014","unstructured":"DiNardo CD, Daver N, Jain N, et al. Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 2014\/04\/01. 2014;28(4):958\u201361. https:\/\/doi.org\/10.1038\/leu.2014.8.","journal-title":"Leukemia 2014\/04\/01"},{"issue":"10","key":"1813_CR26","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/jco.2002.04.117","volume":"15","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol May. 2002;15(10):2429\u201340. https:\/\/doi.org\/10.1200\/jco.2002.04.117.","journal-title":"J Clin Oncol May"},{"issue":"9","key":"1813_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"1","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. Mar 2012;1(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"issue":"12","key":"1813_CR28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"19","author":"MR Savona","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood Mar. 2015;19(12):1857\u201365. https:\/\/doi.org\/10.1182\/blood-2014-10-607341.","journal-title":"Blood Mar"},{"issue":"2","key":"1813_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","volume":"93","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol. 2018;93(2):277\u201385. https:\/\/doi.org\/10.1002\/ajh.24972.","journal-title":"Am J Hematol"},{"issue":"5","key":"1813_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2008","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2008;114(5):937\u201351. https:\/\/doi.org\/10.1182\/blood-2009-03-209262.","journal-title":"Blood"},{"issue":"15","key":"1813_CR31","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","volume":"116","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857\u20138. https:\/\/doi.org\/10.1182\/blood-2010-06-293415.","journal-title":"Blood"},{"key":"1813_CR32","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2024-207736","volume":"144","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Fathima S, Alsugair AK, et al. Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform. Blood. 2024;144:1827\u20131827. https:\/\/doi.org\/10.1182\/blood-2024-207736.","journal-title":"Blood"},{"issue":"10","key":"1813_CR33","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317. https:\/\/doi.org\/10.1182\/blood-2016-05-714030.","journal-title":"Blood"},{"issue":"2","key":"1813_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401\u20138. https:\/\/doi.org\/10.1182\/blood-2011-01-328955.","journal-title":"Blood"},{"issue":"3","key":"1813_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3324\/haematol.2013.093765","volume":"99","author":"R Luthra","year":"2014","unstructured":"Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465\u201373. https:\/\/doi.org\/10.3324\/haematol.2013.093765.","journal-title":"Haematologica"},{"issue":"12","key":"1813_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1002028.","journal-title":"N Engl J Med"},{"issue":"33","key":"1813_CR37","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/jco.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103. https:\/\/doi.org\/10.1200\/jco.2012.42.3863.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1813_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/sim.4780140404","volume":"28","author":"PF Thall","year":"1995","unstructured":"Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med Feb. 1995;28(4):357\u201379. https:\/\/doi.org\/10.1002\/sim.4780140404.","journal-title":"Stat Med Feb"},{"key":"1813_CR39","unstructured":"Kaplan Meier survival analysis was performed using GraphPad. Prism version 10.0.0 for Windows, GraphPad Software, Boston, Massachusetts USA, www.graphpad.com."},{"key":"1813_CR40","unstructured":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"issue":"6","key":"1813_CR41","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"15","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood Mar. 1997;15(6):2079\u201388.","journal-title":"Blood Mar"},{"issue":"12","key":"1813_CR42","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica Dec. 2013;98(12):1865\u201371. https:\/\/doi.org\/10.3324\/haematol.2013.092155.","journal-title":"Haematologica Dec"},{"issue":"6","key":"1813_CR43","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99(6):1142\u201365. https:\/\/doi.org\/10.1002\/ajh.27271.","journal-title":"Am J Hematol"},{"issue":"6","key":"1813_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","volume":"37","author":"L Ad\u00e8s","year":"2013","unstructured":"Ad\u00e8s L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res Jun. 2013;37(6):609\u201313. https:\/\/doi.org\/10.1016\/j.leukres.2013.01.004.","journal-title":"Leuk Res Jun"},{"issue":"4","key":"1813_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cncr.22457","volume":"109","author":"A Aribi","year":"2007","unstructured":"Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007;109(4):713\u20137. https:\/\/doi.org\/10.1002\/cncr.22457.","journal-title":"Cancer"},{"issue":"14","key":"1813_CR46","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","volume":"6","author":"T Braun","year":"2011","unstructured":"Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood Oct. 2011;6(14):3824\u201331. https:\/\/doi.org\/10.1182\/blood-2011-05-352039.","journal-title":"Blood Oct"},{"issue":"12","key":"1813_CR47","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1002\/cncr.25759","volume":"15","author":"R Costa","year":"2011","unstructured":"Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer Jun. 2011;15(12):2690\u20136. https:\/\/doi.org\/10.1002\/cncr.25759.","journal-title":"Cancer Jun"},{"issue":"4","key":"1813_CR48","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","volume":"32","author":"PW Wijermans","year":"2008","unstructured":"Wijermans PW, R\u00fcter B, Baer MR, Slack JL, Saba HI, L\u00fcbbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res Apr. 2008;32(4):587\u201391. https:\/\/doi.org\/10.1016\/j.leukres.2007.08.004.","journal-title":"Leuk Res Apr"},{"issue":"2","key":"1813_CR49","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","volume":"8","author":"L Pleyer","year":"2021","unstructured":"Pleyer L, Leisch M, Kourakli A, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8(2):e135\u201348. https:\/\/doi.org\/10.1016\/S2352-3026(20)30374-4.","journal-title":"Lancet Haematol"},{"key":"1813_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","volume":"31","author":"M Duchmann","year":"2018","unstructured":"Duchmann M, Yalniz FF, Sanna A, et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine May. 2018;31:174\u201381. https:\/\/doi.org\/10.1016\/j.ebiom.2018.04.018.","journal-title":"EBioMedicine May"},{"issue":"15","key":"1813_CR51","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1158\/1078-0432.Ccr-15-2781","volume":"1","author":"E Padron","year":"2016","unstructured":"Padron E, Dezern A, Andrade-Campos M, et al. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res Aug. 2016;1(15):3746\u201354. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2781.","journal-title":"Clin Cancer Res Aug"},{"issue":"22","key":"1813_CR52","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1158\/1078-0432.Ccr-21-0935","volume":"15","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Newman H, Dezern AE, et al. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res Nov. 2021;15(22):6095\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0935.","journal-title":"Clin Cancer Res Nov"},{"key":"1813_CR53","doi-asserted-by":"publisher","unstructured":"Sharma P, Shinde SS, Damlaj M et al. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap syndromes. Leuk Lymphoma. 2017\/04\/03 2017;58(4):872\u201381. https:\/\/doi.org\/10.1080\/10428194.2016.1217529","DOI":"10.1080\/10428194.2016.1217529"},{"key":"1813_CR54","doi-asserted-by":"publisher","unstructured":"Pophali P, Matin A, Mangaonkar AA et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer Journal. 2020\/11\/20 2020;10(11):121. https:\/\/doi.org\/10.1038\/s41408-020-00387-y","DOI":"10.1038\/s41408-020-00387-y"},{"issue":"6","key":"1813_CR55","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41375-025-02620-8","volume":"39","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Hasserjian RP, Rampal RK. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management. Leukemia Jun. 2025;39(6):1311\u201324. https:\/\/doi.org\/10.1038\/s41375-025-02620-8.","journal-title":"Leukemia Jun"},{"issue":"2","key":"1813_CR56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/ejh.14430","volume":"115","author":"N Desai","year":"2025","unstructured":"Desai N, Rodriguez-Rodriguez S, Chen C, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic\/Myeloproliferative Overlap Neoplasms. Eur J Haematol Aug. 2025;115(2):142\u201352. https:\/\/doi.org\/10.1111\/ejh.14430.","journal-title":"Eur J Haematol Aug"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01813-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01813-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01813-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:38:15Z","timestamp":1787787495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01813-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01813-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the MD Anderson Cancer Center Institutional review board.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SL: Participation in Advisory board: Abbvie, Daiichi Sankyo, BluePrint Medicine, Caris Diagnostics, Recordati, Servier, Grants\/contracts: Astellas, Amgen, Honoraria for lectures: Pathology Education Partners; VJ HemeOnc, College of American Pathologists, OncLive, ICCS, MD Education, NCCN, MashUp Media, NCTN, Aptitude Health, Support for meeting\/travel: Pathology Education Partners; VJ HemeOnc, College of American Pathologists, ICCS, MD Education, NCCN, MashUp Media, Binay Foundation.PB: consulting fees from AbbVie, Blueprint Medicines Corporation, Bristol\u2010Myers Squibb, Cogent BioSciences, CTI BioPharma, Dainippon Sumitomo Pharma, Disc Medicine, Geron Corporation, GlaxoSmithKline, Incyte Corporation, Ionis Pharmaceuticals, Jubilant Therapeutics, Karyopharm Therapeutics Inc, Keros Therapeutics, Merck Sharp and Dohme, Morphic Therapeutic, Morphosys, Novartis, Pharma Essentia, Raythera, Sobi, Inc, and Takeda Oncology; fees for other professional activities from GlaxoSmithKline and Merck Sharp and Dohme; grant and\/or contract funding from Ajax Therapeutics, Blueprint Medicines Corporation, Bristol\u2010Myers Squibb, Cogent BioSciences, CTI BioPharma, Dainippon Sumitomo Pharma, Disc Medicine, Geron Corporation, Incyte Corporation, Ionis Pharmaceuticals, Janssen Biotech, Inc, Kartos Therapeutics, Karyopharm Therapeutics Inc, Morphosys, and Telios.LM: advisory board participation with Cogent, GSK, MorphoSys, and PharmaEssentiaTK: Has been a consultant for AbbVie, Agios, BMS, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from AbbVie, BMS, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, GenFleet Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion Therapeutics, GlycoMimetics, and Regeneron Pharmaceuticals; and has received honoraria from Astex PharmaceuticalsCDD: Research Support (to institution): Abbvie, Aprea, Astex, Auron, BMS, Jazz, Remix, Rigel, Servier, Schrodinger, Sillajen, Systimmune. Consultant\/Advisory Boards: Abbvie, Astellas, AZD, BMS, Daiichi Sankyo, Ellipses, GenMab, GSK, MPI, Rigel, Schrodinger, Servier, SyndaxNJS: consulting fees from Amgen, Pfizer Inc, GlaxoSmithKline, Adaptive Biotechnologies, Autolus, and Sanofi; research funding from Takeda Oncology, Astellas Pharma Inc, Xencor, GlaxoSmithKline, NextCure, Ascentage, Novartis, Hemogenyx, and Vironexis; and honoraria from Adaptive Biotechnologies, Novartis, Amgen, Takeda Oncology, Pfizer Inc, Astellas Pharma Inc, and Sanofi.EJ: Research grants and consultancy fees from:, Abbvie, Adapative Biotechnologies, Amgen, Autolus, Ascentage, ASTX\/Taho, Bristol Myers Squibb, Genentech, Novartis, Takeda, Pfizer, TG-RX, TERNSGGM: consulting fees from Bristol Myers Squibb; research support from AbbVie, Astex, Bristol Myers Squibb, Chordia, Curis, Genentech, Novartis, Rigel Pharmaceuticals, and Zentalis; and honoraria from Astex and Curis.NP: Consultancy\/Scientific Advisory Board\/Speaking: Pacylex Pharmaceuticals, Astellas Pharma US, Aplastic Anemia & MDS International Foundation, CareDx, ImmunoGen, Inc, Bristol-Myers Squibb Co., Cimeio Therapeutics AG, EUSA Pharma, Menarini Group, Blueprint Medicines, CTI BioPharma, ClearView Healthcare Partners, Novartis Pharmaceutical, Neopharm, Celgene Corporation, AbbVie Pharmaceuticals, Pharma Essentia, Curio Science, DAVA Oncology, Imedex, Intellisphere, CancerNet, Harborside Press, Karyopharm, Aptitude Health, Medscape, Magdalen Medical Publishing, Morphosys, OncLive, CareDx, Patient Power, Physician Education Resource (PER), PeerView Insitute for Medical Education; Research (grant): United States Department of Defense, National Institute of Health\/National Cancer Institute (NIH\/NCI); Membership on an entity\u2019s Board of Directors\/Management: Dan\u2019s House of Hope; Leadership: ASH Committee on Communications, ASCO Cancer.Net Editorial Board; Licenses: Karger Publishers; Uncompensated: HemOnc Times\/Oncology TimesND: Grants: Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Hanmi, Trovagene, FATE Therapeutics, Novimmune, Glyomimetics, KITE; Consulting fees: Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, Agios, KITE, Stemline\/Menarini. All other authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"58"}}